// App-Quantinova.ai

TMP91 2016 ASA : Phase I Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral Protease-activated Receptor-4 Antagonist BMS-986120

Researchers

Presenter

  • Xuewen Ma

Principal Investigators

  • Zhaoqing Wang

  • Charles E Frost

  • Yan G Ni

  • Jing Yang

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • Bristol-Myers Squibb

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Clopidogrel bisulfate

  • BMS-986120

  • Vorapaxar

  • Evithrom

  • Aspirin

  • Albyl-E

Outcome

  • N/A

Study Design

  • pharmacodynamics

  • randomized

  • double blind/blinded

  • pharmacokinetics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved